18:01 , Oct 20, 2017 |  BC Week In Review  |  Company News

Vir unveils series of deals, additional funding

On Oct. 18, Vir Biotechnology Inc. (San Francisco, Calif.) revealed a crop of new deals and said it has raised more than $500 million to date. CEO George Scangos told BioCentury the company's current round...
00:42 , Aug 12, 2017 |  BioCentury  |  Product Development

HBV test kitchen

Early results for HBV monotherapies are pointing the way toward combinations that could deliver a functional cure. What remains unknown is how many components, and which ones, will prove necessary to eliminate remnants of the...
07:00 , Jul 18, 2016 |  BC Week In Review  |  Clinical News

ALN-HBV: Phase I/II started

Alnylam began a single-blind, placebo-controlled, dose-escalation, U.K. Phase I/II trial of subcutaneous ALN-HBV. The trial will test single doses in up to 24 healthy volunteers and up to 28 patients and multiple doses in up...
08:00 , Dec 15, 2014 |  BC Week In Review  |  Company News

Alnylam pharmaceuticals news

Alnylam outlined plans to focus its RNAi pipeline on genetic medicine, cardio-metabolic diseases and hepatic infectious diseases. Clinical genetic medicine programs include Phase III transthyretin-mediated amyloidosis (ATTR) candidates patisiran and revusiran as well as...
02:31 , Dec 13, 2014 |  BC Extra  |  Clinical News

Alnylam outlines R&D strategy

At its R&D day on Friday, Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) refined its focus on developing RNAi therapeutics across three areas: hepatic infectious disease, genetic medicines and cardiometabolic disease. The company said it is targeting specific...
08:00 , Nov 17, 2014 |  BC Week In Review  |  Company News

Alnylam infectious news

Alnylam unveiled two new RNAi therapeutic candidates in its hepatic infectious diseases portfolio at the American Association for the Study of Liver Diseases (AASLD) meeting. The company's ALN-HDV is designed to treat hepatitis delta...
02:16 , Nov 12, 2014 |  BC Extra  |  Company News

Alnylam adds to hepatic pipeline

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) unveiled two new RNAi therapeutic candidates in its hepatic infectious diseases portfolio at the American Association for the Study of Liver Diseases (AASLD) meeting. The company's ALN-HDV is designed to treat...